VANCOUVER, BC – March 29, 2012 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF) is pleased to announce the closing of a private placement financing (the “Financing”), pursuant to which it has issued 876,042 units at a price of US$1.50 per unit for gross proceeds of US$1,314,063.
Each unit issued consisted of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to purchase an additional common share at US$2.50 per share for a period of 24 months from the closing of the Financing. An initial tranche of 66,304 Units for gross proceeds of US$99,456 closed on February 29, 2012. The Company intends to close one or more additional tranches of the Financing in coming weeks at the same price of US$1.50 per unit on the same terms as set forth above.
All securities issued in connection with the Financing are subject to a hold period in accordance with applicable Canadian and United States securities laws. Proceeds of the Financing will be used for general working capital requirements.
None of the securities sold in the Financing have been or will be registered under the United States Securities Act of 1933, as amended (the “Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Act.
On Behalf of the Board of Directors,
Peter Jensen, Chairman of the Board
NOT FOR DISSEMINATION IN THE UNITED STATES